Entering text into the input field will update the search result below

PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q4 2017 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

PTC Therapeutics (NASDAQ:PTCT) Q4 2017 Earnings Conference Call March 6, 2018 4:30 PM ET


Emily Hill - Head of Investor Relations

Stuart Peltz - Chief Executive Officer

Marcio Souza - Chief Operating Officer

Christine Utter - Principal Financial Officer and Treasurer


Derek Yuan - Credit Suisse

Joel Beatty - Citi

Eric Joseph - JP Morgan Chase

Tazeen Ahmad - Bank of America

Gena Wang - Barclays

Raju Prasad - William Blair

Brian Abrahams - RBC Capital Markets


Good day, ladies and gentlemen, and welcome to the PTC Therapeutics Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]

And I would now like to introduce your host for today’s conference, Miss. Emily Hill, Head of Investor Relations. Ma'am you may begin.

Emily Hill

Thanks. Hi, good afternoon, and thank you for joining us to discuss our 2017 fourth quarter and full-year corporate updates and financial results. Joining me on today's call is our CEO, Stuart Peltz, our Chief Operating Officer, Marcio Souza and our Principal Financial Officer Christine Utter.

Before I had the call over to Stuart, I would like to remind you that today we will be making forward-looking statements. These statements include all statements other than those of historical facts, including statements concerning financial guidance, our expectations with respect to the future commercial availability of and access to EMFLAZA and Translarna the timing and outcome of any future re-submission of an NDA for Translarna to the FDA, our future expectations regarding other clinical, regulatory and commercialization matters, including with respect to potential outcomes and anticipated timelines, anticipated timelines of our SMA collaboration with Roche, addressable per patient populations for Translarna and EMFLAZA, and the potential success of Translarna for the treatment of nmDMD

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.